Immunovant’s investigational product candidate, IMVT-1401 (“batoclimab”) is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection on a convenient weekly, or less frequent, dosing schedule.